|
| | (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide Basic information |
| Product Name: | (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide | | Synonyms: | Sch 527123;(R)-2-hydroxy-N,N-diMethyl-3-((2-((1-(5-Methylfuran-2-yl)propyl)aMino)-3,4-dioxocyclobut-1-en-1-yl)aMino)benzaMide;(R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3;(R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide;3-[[3-[(Dimethylamino)carbonyl]-2-hydroxyphenyl]amino]-4-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]cyclobut-3-ene-1,2-dione;SCH527123, Navarixin;Benzamide, 2-hydroxy-N,N-dimethyl-3-[[2-[[(1R)-1-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]-;2-Hydroxy-N,N-dimethyl-3-[[2-[[(1R)-1-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl | | CAS: | 473727-83-2 | | MF: | C21H23N3O5 | | MW: | 397.42 | | EINECS: | | | Product Categories: | | | Mol File: | 473727-83-2.mol |  |
| | (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide Chemical Properties |
| Melting point | 118-120℃ | | Boiling point | 548.7±60.0 °C(Predicted) | | density | 1.34 | | storage temp. | Refrigerator | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 7.93±0.50(Predicted) | | form | Solid | | color | Light Yellow to Yellow |
| | (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide Usage And Synthesis |
| Uses | Sch 527123 is a potent CXCR2 antagonist. It can potentially inhibits human colon cancer liver metastasis. | | General Description | A cell-permeable, orally active, non-toxic, cyclobutenedione compound with anti-inflammatory properties. Acts as a specific, high-affinity, and potent allosteric antagonist of CXCR2 (IC50 = 2.6 nM for human; Kd = 49, 200, and 80 pM for human, rat, and cynomolgus, respectively). Also exhibits high potency against CXCR1 (IC50 = 36 nM for human, Kd = 3.9 and 41 nM for human and cynomolgus, respectively). Displays excellent selectivity over CXCR3, CCR5, and a large panel of GPCRs, enzymes and ion channels (~ 10 μM). Potently inhibits CXCL1- and CXCL8-induced chemotaxis in human neutrophils (hPMN; IC50<1 nM and 16 nM, respectively). Shown to suppress pulmonary neutrophilia (ED50 = 1.3 mg/kg), goblet cell hyperplasia (ED50 = 700 mg/kg), and increase bronchoalveolar lavage (BAL) mucin content (ED50 ≤ 1 mg/kg) in rats subjected to vanadium pentoxide induced pulmonary inflammation. Inhibits melanoma cell proliferation (~ 1 mg/ml) by suppressing the phosphorylation of ERK1/2. Diminishes the invasive potential of melanoma cells and blocks angiogenesis in mice (100 mg/kg, p.o., q.d for 21 days). Exhibits desirable pharmacokinetic properties.
Please note that the molecular weight for this compound is batch-specific due to variable water content. | | Biological Activity | sch-527123 is a novel, selective cxc chemokine receptor 2 (cxcr2) antagonist.sch-527123 was able to suppress cxcr2-mediated signal transduction as shown through decreased phosphorylation of the nf-κb/mitogen-activated protein kinase (mapk)/akt pathway [1].cells were treated with increasing concentrations of sch-527123 for 72 hours and showed dose-dependent growth inhibitory activity with ic50 (72 h) values ranging from 18 to 40 μmol/l. importantly the il-8–overexpressing cells showed a higher ic50 (72 h) concentration of sch-527123 than parental cells [hct116 and e2 (p < 0.005): 28.9 ± 0.02 μmol/l and 39.5 ± 0.01 μmol/l, respectively; caco2 and iiie (p < 0.005): 18.8 ± 0.03 μmol/l and 25.5 ± 0.02 μmol/l, respectively]. therefore, sch-527123 decreased growth inhibitory activity in colorectal cancer cell lines [2]. | | Biochem/physiol Actions | Cell permeable: yes | | target | CXCR1 | | references | [1]. holz o, khalilieh s, ludwig-sengpiel a et al. sch527123, a novel cxcr2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. holz o1, khalilieh s, ludwig-sengpiel a et al.
[2]. holz o1, khalilieh s, ludwig-sengpiel a et al. the cxcr2 antagonist, sch-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. mol cancer ther. 2012 jun;11(6):1353-64. |
| | (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide Preparation Products And Raw materials |
|
